Protara Therapeutics Inc (TARA) is a Healthcare · Biotechnology company listed on NASDAQ. Price $3.70 (+0.00%), Market cap $0.26B, 52-week low–high $2.78 ~ $7.56.
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.
Financial statements, price targets, institutional (13F) holdings and related news for Protara Therapeutics Inc are updated in real time on BlackAll Trade.
Protara Therapeutics Inc trades at $3.70 (+0.00%). Real-time quotes and charts are available on BlackAll Trade.
Protara Therapeutics Inc has a market cap of about $0.26B.
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-